Latest news with #OvarianCancer
Globe and Mail
8 hours ago
- Business
- Globe and Mail
Ovarian Cancer Market Forecast to 2034: Advancing Treatment Frontiers and Epidemiological Shifts
Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific symptoms and a lack of effective early screening. It encompasses a spectrum of histological subtypes, including high-grade serous (HGSOC), low-grade serous (LGSOC), and epithelial tumors, each with unique biological and clinical features. High recurrence rates and poor long-term survival continue to drive the urgent need for improved treatment options and earlier detection. DelveInsight's latest report, ' Ovarian Cancer – Market Insight, Epidemiology, and Market Forecast – 2034,' provides a comprehensive overview of the disease's burden across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It offers in-depth segmentation by subtype, stage, age group, and biomarker status, alongside historical and projected epidemiological trends. The analysis highlights rising incidence rates, shifting subtype proportions—particularly serous carcinomas—and the evolving landscape of diagnostic and therapeutic innovation. The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic agents, and emerging targeted therapies. These options have shifted the treatment paradigm, particularly for BRCA-mutated, HRD-positive, and platinum-sensitive disease. Nonetheless, persistent issues such as chemoresistance, limited options in late-line settings, and variability in biomarker testing are hindering further progress. Looking ahead, the market is anticipated to grow steadily through 2034, propelled by innovations in epigenetic modulators, antibody-drug conjugates (ADCs), immune-oncology combinations, and advanced diagnostics like liquid biopsies. Enhanced biomarker testing and personalized treatment strategies will support optimized patient care. DelveInsight's full report explores pipeline highlights, market drivers and barriers, and strategic recommendations for stakeholders aiming to transform the outlook for ovarian cancer patients. Request a sample and uncover the latest breakthroughs shaping the Ovarian Cancer market landscape and future outlook Some of the key insights of the Ovarian Cancer Market Report: • In 2024, the ovarian cancer market in the 7MM was valued at USD 2.7 billion. • Market size is expected to grow with the launch of new ovarian cancer therapies. • The U.S. held the largest share, reaching USD 1.92 billion in 2024. • Total incident ovarian cancer cases in the 7MM were 61K in 2024. • The U.S. reported the highest number of high and low-grade serous ovarian cancer cases. • There were approximately 37.6K serous ovarian cancer cases in the 7MM in 2024. • In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and an Ovarian Cancer mouse model. • In April 2025, Biocon Biologics received FDA approval for JOBEVNE (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. JOBEVNE is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer. • In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer. • Emerging therapies for ovarian cancer include Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Key companies involved in the treatment of ovarian cancer include Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. Curious to see the graphical version of these numbers? The ovarian cancer infographic is ready for you. Check it out here! Ovarian Cancer Overview Ovarian cancer is a complex and often late-diagnosed malignancy arising from the epithelial cells, stromal cells, or germ cells of the ovary. Among these, epithelial ovarian cancer is the most prevalent, accounting for over 90% of malignant ovarian tumors. Due to its subtle early symptoms and lack of reliable screening methods, the disease is frequently diagnosed at advanced stages, contributing to its high mortality rate among gynecological cancers. The most common and aggressive subtype is High-Grade Serous Ovarian Cancer (HGSOC), which often presents with widespread peritoneal metastases. In contrast, Low-Grade Serous Ovarian Cancer (LGSOC) tends to follow a more indolent course but shows resistance to standard chemotherapy, highlighting a critical unmet need for targeted therapies. Genetic mutations such as BRCA1/2 and alterations in the MAPK pathway (BRAF/KRAS/NRAS/NF1) and homologous recombination deficiency (HRD) status play a pivotal role in disease stratification and therapy selection. Over the past decade, the ovarian cancer treatment landscape has evolved with the introduction of PARP inhibitors, anti-angiogenic agents, and targeted therapies that have significantly improved outcomes in biomarker-driven subpopulations. Despite these advancements, resistance development, limited options for certain subtypes like LGSOC, and high relapse rates continue to challenge long-term disease control. As research progresses, efforts are focused on improving early diagnosis, personalizing treatment based on molecular profiling, and expanding therapeutic options through clinical trials and novel drug development. Get a free sample for the Ovarian Cancer market forecast, size & share analysis report: Ovarian Cancer Epidemiology The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends. Ovarian Cancer Epidemiology Segmentation: The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: • Total incident cases of Ovarian Cancer • Age-specific cases of Ovarian Cancer • Type-Specific Cases of Ovarian Cancer • Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer • Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer Ovarian Cancer Drugs Uptake and Pipeline Development Activities The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Ovarian Cancer throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments. The Therapeutics Assessment further highlights the Ovarian Cancer drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction. Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Ovarian Cancer, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Ovarian Cancer therapeutics. Ovarian Cancer Market Outlook The ovarian cancer treatment landscape is undergoing a significant transformation, with the integration of targeted therapies, personalized medicine, and ongoing clinical research aimed at improving long-term outcomes. High-grade serous ovarian cancer (HGSOC), the most prevalent subtype, continues to be treated with a combination of surgery and platinum-based chemotherapy. However, the emergence of maintenance therapies—especially PARP inhibitors—has reshaped post-treatment strategies for patients with BRCA or HRD mutations, helping reduce recurrence rates and extend progression-free survival. The future of ovarian cancer care is increasingly personalized, with clinical trials exploring novel options like immunotherapy, vaccine-based approaches, and radiation strategies for advanced or recurrent disease. These innovations reflect a broader trend toward therapies tailored to molecular profiles and disease stage, moving away from one-size-fits-all treatment. However, disparities in access to care remain a major challenge. Socioeconomic, racial, and geographic barriers often limit timely diagnosis and appropriate treatment, particularly in underserved populations. As awareness of BRCA testing and biomarker-driven treatment grows, expanding access to genetic screening and oncology expertise will be crucial. The ovarian cancer market is expected to expand steadily through 2034, driven by rising disease burden, evolving therapeutic options, and a growing emphasis on precision medicine. Addressing current gaps in care delivery, especially among high-risk and underserved groups, will be essential to unlocking the full potential of these medical advancements. Ovarian Cancer Market Drivers • The introduction of PARP inhibitors (e.g., olaparib, niraparib) and other targeted agents based on BRCA and HRD status has revolutionized ovarian cancer treatment, improving survival and reducing recurrence in select patient groups. • Increasing adoption of genetic and molecular testing for BRCA mutations, HRD status, and other biomarkers is enabling personalized treatment strategies, driving demand for advanced therapeutic options. Ovarian Cancer Market Barriers • The absence of reliable early screening methods and vague initial symptoms often lead to diagnosis at advanced stages, limiting curative treatment options and affecting patient outcomes. • Limited access to specialized oncology care, especially in rural and low-income regions, along with underutilization of genetic testing among minority populations, continues to hinder equitable treatment and diagnosis. Scope of the Ovarian Cancer Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]. • Key Ovarian Cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. • Key Ovarian Cancer Therapies: Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Ovarian Cancer Therapeutic Assessment: Ovarian Cancer currently marketed, and Ovarian Cancer emerging therapies. • Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers. • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies. • Ovarian Cancer Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement. Table of Contents 1. Ovarian Cancer Market Report Introduction 2. Executive Summary for Ovarian Cancer 3. SWOT analysis of Ovarian Cancer 4. Ovarian Cancer Patient Share (%) Overview at a Glance 5. Ovarian Cancer Market Overview at a Glance 6. Ovarian Cancer Disease Background and Overview 7. Ovarian Cancer Epidemiology and Patient Population 8. Country-Specific Patient Population of Ovarian Cancer 9. Ovarian Cancer Current Treatment and Medical Practices 10. Ovarian Cancer Unmet Needs 11. Ovarian Cancer Emerging Therapies 12. Ovarian Cancer Market Outlook 13. Country-Wise Ovarian Cancer Market Analysis (2020–2034) 14. Ovarian Cancer Market Access and Reimbursement of Therapies 15. Ovarian Cancer Market Drivers 16. Ovarian Cancer Market Barriers 17. Ovarian Cancer Appendix 18. Ovarian Cancer Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
The Sun
29-05-2025
- General
- The Sun
The 2 surprising factors that ‘increase your breast cancer risk' as Kara Tointon reveals brave mastectomy
BREAST cancer, it's a disease we've all heard of - most of us will know someone affected - but do you know your risk of developing it? Yesterday, former EastEnders star Kara Tointon revealed she's taken the decision to have a double mastectomy after discovering she carries a gene that increases her risk. But did you know, there are everyday factors that can influence your chances of the disease - including your height? 8 8 The 41-year-old posted an Instagram video to raise awareness of the preventative measure, after discovering she was at risk of both breast and ovarian cancer. She said: "You may have heard of the BRCA genes 1 and 2 and as a carrier it means I am at a greater risk of both breast and ovarian cancer." The soap star was asked to take a genetics test when her mum Carol was undergoing treatment for ovarian cancer back in 2018. Sadly, her mum died in 2019. After having her second son in 2021 and deciding her family was complete, she underwent two preventative surgeries - the first a double mastectomy and the second a two-part procedure involving the removal of the fallopian tubes and later the ovaries. BRCA stands for BReast CAncer. It refers to the BRCA1 and BRCA2 genes, which are tumor suppressor genes that play a role in DNA repair and preventing uncontrolled cell growth. When these genes have alterations (mutations), it can increase the risk of developing breast cancer and other cancers. According to Dr Deborah Lee, of Dr Fox Online Pharmacy, women who carry abnormal BRAC 1 and BRAC2 genes have an 85 per cent increased lifetime risk of breast cancer. She added: "Breast cancer is more likely to occur at an earlier age and to affect both breasts. "The risk of ovarian cancer is also increased." Individuals are at a higher risk of carrying BRCA1 or BRCA2 gene mutations if they have a family history of breast, ovarian, or prostate cancer, particularly if multiple close relatives have been diagnosed. If you think you could be at risk, Dr Lee advises seeing your GP. She said: "After a consultation, you may be referred for predictive genetic testing. "There are pros and cons of having the predictive test and not everyone will want to have it. "Before you have the test, you will be offered genetic counselling. The test is a blood test." Two risk factors that might surprise you BRCA genes aren't the only risk factor for breast cancer. Dr Kerri Palmer-Quinn, senior scientific research officer at Breast Cancer UK, says the biggest risk factor is ageing - something we unfortunately cannot control. Like many cancers, family history of the disease and various lifestyle and environmental factors can also influence your risk But other risk factors for breast cancer may surprise you. Being tall Studies suggest there's a slight link between height and breast cancer risk, with taller women potentially having a slightly higher chance of developing the disease. Dr Palmer-Quinn said: "Being tall can slightly increase your risk of breast cancer. "The reasons behind this association are still being investigated, however it may be linked to the growth spurts taller woman have during early development. "These growth spurts mean that taller women may have higher levels of certain growth factors as well as the growth hormone insulin-like growth factor 1 (IGF-1). "IGF-1 can promote cell growth and prevent programmed cell death which can increase the risk of cancer, including breast cancer." High breast density 8 Having high breast density (also known as mammographic density) is a strong risk factor for breast cancer. Dr Palmer-Quinn explained: "having dense breasts means you have higher proportions of fibrous and glandular tissue which is where breast cancers are more likely to arise, in comparison to fat tissue. "Breast density can only be determined by a mammogram scan and isn't related to how your breasts look or feel. "Having dense breasts can make these mammogram scans more difficult to interpret meaning potential cancers are harder to identify. "Breast density can be influenced by your genetics and potentially the environment; it also may change overtime and tends to reduce with age." Other risk factors to be aware of While some breast cancer risk factors are unavoidable, including age, others are modifiable and can be addressed to potentially lower your risk. Weight gain throughout adulthood Weight gain throughout adulthood increases the risk of postmenopausal breast cancer; particularly if the weight gain occurs after menopause has taken places, advised Dr Palmer-Quinn. She added: "After menopause, the body's production of the sex hormone oestrogen shifts from the ovaries to fat tissue. Therefore, increased body fat can lead to higher levels of circulating oestrogen, which is a known risk factor for breast cancer. "In addition, excess body fat can contribute to chronic inflammation and disrupt hormone regulation in ways that may further increase breast cancer risk." What you can do: To maintain a healthy weight, focus on a balanced diet, regular physical activity, and healthy lifestyle habits. Prioritise fruits, vegetables, whole grains, and lean proteins, and limit sugary drinks and processed foods. Aim for at least 150 minutes of moderate-intensity aerobic exercise per week. Alcohol consumption 8 Any level of alcohol consumption can increase the risk of developing breast cancer - there is no safe threshold. Dr Palmer-Quinn explained: "Alcohol raises levels of circulating oestrogen. "It is also broken down into acetaldehyde, a compound that can damage DNA and potentially lead to cancer. "Additionally, alcohol can contribute to weight gain, which may further increase risk, particularly after menopause." What you can do: When it comes to giving up alcohol it can help to tell your family and friends that you're aiming to stop drinking alcohol and explain why. This way, you can share your successes with them, and they'll understand why you've started turning down drinks or trips to the pub. Try to identify the times when you would usually drink and fill the gap with something else. And remember to enjoy the benefits, including weight loss, better sleep, and more energy. Smoking Studies have shown a small but statistically significant increased risk of breast cancer in women who smoke compared to those who have never smoked. Dr Lee said: "Current smoking increases the risk of breast cancer by 10 per cent compared to those who have never smoked." What you can do: The most effective way to quit smoking is to combine nicotine replacement therapy (NRT) or other medications with professional support from a local stop smoking service. Lack of exercise A lack of physical activity is a well-established risk factor for breast cancer. Dr Lee explained: "Regular physical activity has been shown to reduce the risk of breast cancer by around 20 per cent. "Exercise lowers hormone levels and reduces inflammation as well as helping control body weight." What you can do: To begin exercising, start with low-impact activities like brisk walking, swimming, or yoga, and gradually increase intensity and duration. Set realistic goals, choose activities you enjoy, and schedule exercise into your routine. Consider finding an exercise buddy, using a journal or app to track progress, and varying your workouts to stay motivated. As well as doing what you can to reduce your risk of breast cancer, make sure you're well aware of the symptoms to look out for - see a GP if you experience any of the below...
Yahoo
14-05-2025
- Health
- Yahoo
The Dr. Scott Kamelle Inspiration Award for Ovarian Cancer Survivors: Recognizing the Enduring Spirit and Inspiring Journeys of Survivors Nationwide
Milwaukee, Wisconsin--(Newsfile Corp. - May 14, 2025) - Dr. Scott Kamelle, a prominent and compassionate figure in gynecologic oncology, has established a significant initiative: the Dr. Scott Kamelle Inspiration Award for Ovarian Cancer Survivors. This one-time $1,000 award is dedicated to celebrating the enduring spirit, remarkable journeys, and inspiring personal triumphs of women who have overcome ovarian cancer. It provides a platform for survivors to share their powerful stories and offer a beacon of hope to others. The Dr. Scott Kamelle Inspiration Award for Ovarian Cancer Survivors: Recognizing the Enduring Spirit and Inspiring Journeys of Survivors Nationwide To view an enhanced version of this graphic, please visit: Dr. Kamelle: A Career Dedicated to Women's Health and Empowerment Throughout his distinguished career, Dr. Scott Kamelle has been a tireless advocate for the well-being and empowerment of women facing ovarian and uterine cancers. His strong academic background, including a Bachelor of Science in Chemistry from the University of California, Berkeley, and a medical degree from Boston University School of Medicine, laid the groundwork for his specialized training in Obstetrics and Gynecology at the University of Pennsylvania and a fellowship in Gynecologic Oncology at the University of Oklahoma Health Sciences Center. From his role as an Associate Professor at the University of Wisconsin-Madison to his leadership of Aurora Health Care's Robotic Steering Committee for over a decade, Dr. Scott Kamelle's contributions have been transformative. His commitment to clinical research and advocacy has advanced knowledge in critical areas such as ovarian carcinoma and HPV prevalence, always prioritizing patient-centered care and education. Shining a Light on Resilience: The Award's Core Mission This award embodies Dr. Scott Kamelle's long-standing commitment to highlighting the extraordinary courage and unwavering resilience of ovarian cancer survivors. It is open to women of all ages and backgrounds who have successfully completed their treatment and are currently in remission. The award's focus is not on academic or professional achievements, but rather on the profound personal experiences of resilience and the survivor's capacity to inspire others through their story. Who Can Inspire? Eligibility Guidelines Applicants for the Dr. Scott Kamelle Inspiration Award must be ovarian cancer survivors who are in remission after completing their prescribed treatment. While undergraduate students are eligible, the program does not limit applicants based on academic or professional accomplishments. The emphasis is firmly on the individual's inspiring journey. Sharing Your Journey: The Heart of the Application A central component of the application process is a compelling essay where applicants reflect on their experiences as ovarian cancer survivors. This essay should articulate the challenges faced during treatment, the significant triumphs achieved, and the valuable lessons learned throughout their journey. Applicants are encouraged to share how their experiences have shaped their lives and how they have used their stories to uplift and provide support to others. These authentic submissions should be limited to a maximum of 1,000 words. The Ripple Effect of Storytelling: Fostering Hope and Connection Dr. Scott Kamelle believes deeply in the power of shared narratives to inspire hope and build a strong sense of community among individuals facing similar challenges. By providing a platform for these stories to be heard, the award aims to showcase the journeys of survivors as powerful sources of strength and unwavering determination. Important Dates: Application Closure and Winner Announcement The deadline for submitting applications for the Dr. Scott Kamelle Inspiration Award for Ovarian Cancer Survivors is September 15, 2025. The winner, who will receive a one-time award of $1,000, will be announced on October 15, 2025. About Dr. Scott Kamelle: A Dedicated Advocate Dr. Scott Kamelle is a highly respected expert in gynecologic oncology with a career marked by significant contributions to the field. His professional roles have included Associate Professor at the University of Wisconsin-Madison, Director of Gynecologic Oncology at Aurora Health Care in Milwaukee, and Chair of Aurora Health Care's Robotic Steering Committee. A committed researcher, Dr. Kamelle has made substantial advancements in the understanding and treatment of ovarian and uterine cancers. Through initiatives like the Dr. Scott Kamelle Inspiration Award for Ovarian Cancer Survivors, he continues his legacy of uplifting the ovarian cancer community, encouraging innovation, and providing survivors with a valuable opportunity to inspire and support others. Discover More and Apply: For detailed information about the award, including eligibility requirements and the application process, please visit: . This award reflects Dr. Scott Kamelle's unwavering dedication to celebrating the inspiring spirit and courage of ovarian cancer survivors, offering them a meaningful avenue to share their unique stories and serve as a source of inspiration for the wider community. Contact Information: Spokesperson: Dr. Scott KamelleOrganization: Dr. Scott Kamelle AwardWebsite: Email: apply@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CTV News
09-05-2025
- Entertainment
- CTV News
Lady Ball gala held in Halifax
The annual Lady Ball fundraising gala in support of Ovarian Cancer Canada was held in Halifax Thursday night.
